Advent Life Sciences Raises £145.5M (USD 235M) for its Second Life Sciences Venture Capital Fund

Press Release:


Advent Life Sciences Raises £145.5M (USD 235M) for its Second Life Sciences Venture Capital Fund


London, UK, October 28 2014. - Advent Life Sciences today announced the closing of Advent Life Sciences Fund II (ALSF II), a £145.5M (USD 235M) venture capital fund raised to seed and build life sciences companies in the UK, Europe and the US. The Fund will back entrepreneurs and early-stage and mid-stage companies with the potential to deliver first- or best-in-class breakthrough products for unmet medical needs. The Fund, which quickly exceeded its target, was raised entirely from independent financial investors including funds-of-funds, pension funds, and family offices.

The full press release is available on Advent Life Sciences website.

 

Contact
Advent Life Sciences
Raj Parekh, General Partner
Phone : +44(0)207 932 2100
Email : Raj.Parekh@adventLS.com

Back